Search

Nobel prize goes to immunotherapy researchers

October 1, Sweden - Cancer kills millions of people every year and is one of humanity’s greatest health challenges.

Read more

Meeting program

Thursday, October 12*All times are in EET.

Read more

The importance of education and collaboration for the treatment of patients

This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Report VIRTUAL EHA-SWG Scientific Meeting on Immunotherapy

This scientific meeting was organized together with the EHA Scientific Working Group on Immune Therapies for Hematological Disorders.

Read more